Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT3SZBT)

• DTT Name: von Willebrand factor (VWF) DTT Info
• Gene Name: VWF

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caplacizumab	DMPUKA7	Thrombotic thrombocytopenic purpura	3B64.14	Approved	[1]
Vonvendi	DMI783H	Von willebrand disease	3B12	Approved	[2]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALX-0081	DM7EBH9	Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[3]
Recombinant von Willebrand factor/recombinant Factor VIII complex	DM7JFDO	Von willebrand disease	3B12	Phase 3	[4]
ARC1779	DM7PCLY	Intracranial embolism	8B22.1	Phase 2	[5]
BT-200	DM1EYOF	Von willebrand disease	3B12	Phase 2	[6]
DA-697b	DMBRN2G	Thrombosis	DB61-GB90	Phase 1	[7]
DTRI-031	DM0BCT7	Ischemic stroke	8B11.5Z	Phase 1	[8]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mitoflaxone	DMO06JV	Solid tumour/cancer	2A00-2F9Z	Terminated	[9]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Auryntricarboxylic acid (ATA)	DMOIQ4K	Discovery agent	N.A.	Investigative	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Clinical pipeline report, company report or official report of Vonvendi.
• [3] Clinical pipeline report, company report or official report of Ablynx
• [4] 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
• [5] Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
• [6] Clinical pipeline report, company report or official report of Guardian Theapeutics
• [7] A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
• [8] Clinical pipeline report, company report or official report of Basking Biosciences
• [9] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.